Hypophysitis Induced by Monoclonal Antibodies to Cytotoxic T Lymphocyte Antigen 4: Challenges from a New Cause of a Rare Disease

Author:

Torino Francesco1,Barnabei Agnese2,De Vecchis Liana3,Salvatori Roberto4,Corsello Salvatore M.5

Affiliation:

1. a Department of Internal Medicine, University of Rome “Tor Vergata,” Rome, Italy;

2. c Endocrinology Unit, National Institute of Cancer “Regina Elena,” Rome, Italy;

3. b Department of Neuroscience, University of Rome “Tor Vergata,” Rome, Italy;

4. d Pituitary Center, Division of Endocrinology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA;

5. e Endocrinology Unit, Università Cattolica, Rome, Italy

Abstract

Learning Objectives: After completing this course, the reader will be able to: Identify symptoms of hypophysitis as an infrequent immune related side effect of ipilimumab and other anti-CTLA-4 monoclonal antibodies.Select the appropriate diagnostic and therapeutic work-up for patients suspected of having anti-CTLA-4 monoclonal-induced hypophysitis. CME This article is available for continuing medical education credit at CME.TheOncologist.com Specific human monoclonal antibodies antagonize cytotoxic T-lymphocyte antigen 4 (anti–CTLA-4 mAbs), a negative regulator of the immune system, inducing unrestrained T-cell activation. In patients with advanced or metastatic melanoma, one of these agents, ipilimumab, produced considerable disease control rates and, for the first time, a clear improvement in overall survival outcomes. However, accumulating clinical experience with anti–CTLA-4 mAbs identified a novel syndrome of autoimmune and autoinflammatory side effects, designated as “immune-related adverse events,” including mainly rash, colitis, and hepatitis. Autoimmune hypophysitis has emerged as a distinctive side effect induced by anti–CTLA-4 mAbs. This condition may be life threatening because of adrenal insufficiency if not promptly recognized, but it may easily be diagnosed and treated if clinically suspected. Hypopituitarism caused by these agents is rarely reversible and prolonged or life-long substitutive hormonal treatment is often required. The precise mechanism of injury to the pituitary triggered by anti–CTLA-4 mAbs is yet to be fully elucidated.

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Reference81 articles.

1. Clinical development of the anti-CTLA-4 antibody tremelimumab;Ribas;Semin Oncol,2010

2. Phase III, open-label, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma;Ribas;J Clin Oncol,2008

3. Improved survival with ipilimumab in patients with metastatic melanoma;Hodi;N Engl J Med,2010

4. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma;Robert;N Engl J Med,2011

5. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis;Yang;J Immunother,2007

Cited by 68 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3